Unlock this StockReport nowClick to Unlock

Sanofi SA Share Price

GCVRZ $0.525 -0.0  -1.2%
5:25pm
StockRank

Momentum
Relative Strength (%)
1m
3m
1yr
Volume Change (%)
10d v 3m
Price vs... (%)
52w High
50d MA
200d MA
vs.
market
vs.
industry
Growth & Value
Margin of Safety (beta)
Screens Passed 2
Balance Sheet · Income Statement · Cashflow Financial Summary
Year End 31st Dec 2013 2014 2015 2016 2017 2018 2019E 2020E CAGR / Avg
Revenue €m
Operating Profit €m
Net Profit €m
EPS Reported
EPS Normalised
EPS Growth %
PE Ratio x
PEG x
Profitability
Operating Margin %
ROA %
ROCE %
ROE %
Cashflow
Op. Cashflow ps
Capex ps
Free Cashflow ps
Dividends
Dividend ps
Dividend Growth %
Dividend Yield %
Dividend Cover x
Balance Sheet
Cash etc €m
Working Capital €m
Net Fixed Assets €m
Net Debt €m
Book Value €m
Average Shares m
Book Value ps +1.9%

FINANCIAL BRIEF: For the three months ended 31 March 2019, Sanofi SA revenues increased 7% to EUR8.71B. Net income before extraordinary items increased 12% to EUR1.14B. Revenues reflect Pharmaceuticals-Dupixent segment increase from EUR107M to EUR329M, Pharmaceuticals-Eloctate segment increase from EUR43M to EUR174M, United States segment increase of 16% to EUR2.55B, Asia segment increase of 21% to EUR1.21B. more »

Health Trend
Bankruptcy Risk
  Earnings Manipulation Risk
Magic Formula Score
B-
B-
Other Ratios
Leverage (ttm) Total -Intang +Pension
Gross Gearing %
Net Gearing %
Cash / Assets %
vs.
market
vs.
industry
Recent History
Latest interim period (ended 31st Dec '18) vs. prior year
Sales Growth %
EPS Growth %
3yr Compound Annual Growth Rate
Sales Growth %
EPS Growth %
DPS Growth %

Broker Forecasts
31st Dec 2019
31st Dec 2020

Price Target: €84.1
(+17,6421% above Price)
Net Profit EPS DPS Net Profit EPS DPS
Est. Long Term Growth Rate: +5.7% (€) (€) (€) (€) (€) (€)
Consensus Estimate
1m Change
3m Change
24 brokers Broker Consensus Trend
Broker Recommendations for Sanofi SA
Recommendation:Strong SellSellHoldBuyStrong Buy
No. of Analysts: 0 0 11 6 7

Named Brokers and Analysts
There are no named brokers.

Profile Summary

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company's pharmaceuticals operations. The Vaccines segment is dedicated to vaccines and includes the commercial operations of the Company's vaccines division Sanofi Pasteur and dedicated research and development, production and marketing activities for the Company's vaccines operations. Its Rare Diseases products include Cerezyme, Cerdelga, Myozyme and Lumizyme, Fabrazyme, and Aldurazyme. It partners with Alnylam Pharmaceuticals.

Directors: Serge Weinberg (CHM) 68, Olivier Brandicourt (CMG) 63, Jean-Baptiste Chasseloup de Chatillon (CFO) 54, Karen Linehan (EVP) 60, Caroline Luscombe (EVP) 59, Dominique Carouge (EVP) , Olivier Charmeil (EVP) 56, David Loew (EVP) , Philippe Luscan (EVP) 57, Alan Main (EVP) 65, Laurent Attal (DRC) 61, Christophe Babule (DRC) , Emmanuel Babeau (IND) 52, Bernard Charles (IND) 62, Claudie Haignere (IND) 61,

No. of Employees: 104,226 No. of Shareholders: n/a


Last Annual December 31st, 2018
Last Interim December 31st, 2018
Incorporated May 11, 1994
Public Since July 1, 2002
Shares in Issue 1,245,454,385
Free Float 1.11bn (89.2%)
Sector Healthcare
Industry Pharmaceuticals
Index
Exchange NASDAQ Global Market (Dual Listing)
Eligible for an ISA? a SIPP?

Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2019.


Should you buy GCVRZ

Access GCVRZ Analytics Now!

FREE TRIAL or TAKE THE TOUR
Let’s get you setup so you get the most out of our service
Done, Let's add some stocks
Brilliant - You've created a folio! Now let's add some stocks to it.

  • Apple (AAPL)

  • Shell (RDSA)

  • Twitter (TWTR)

  • Volkswagon AG (VOK)

  • McDonalds (MCD)

  • Vodafone (VOD)

  • Barratt Homes (BDEV)

  • Microsoft (MSFT)

  • Tesco (TSCO)
Save and show me my analysis